Bajaj Healthcare Soars 7% as Q3 FY26 Profit Jumps 34% to ₹15.67 Crore; Revenue Up 31% to ₹161 Crore

Bajaj Healthcare share price (NSE: BAJAJHCARE) gained sharply on January 19 after the company announced strong December quarter earnings. The stock jumped over 7% during the session and touched an intraday high of ₹419.55 on the BSE. Around mid-morning, it was trading near ₹398, outperforming the broader market.

The company’s market capitalisation stands at ₹1,256 crore. The stock’s 52-week range is between ₹379 and ₹745.

Bajaj Healthcare Net Profit Rises 34% YoY

For Q3FY26, Bajaj Healthcare reported a net profit of ₹15.67 crore, compared to ₹11.72 crore in the same quarter last year. This reflects a strong year-on-year growth of 33.7%.

Revenue Shows Healthy Growth

Revenue from operations increased to ₹161.22 crore, up 31.3% from ₹122.8 crore a year earlier. The growth was supported by higher demand across APIs and formulations.

EBITDA Improves

EBITDA for the quarter rose 34.6% to ₹32.33 crore from ₹24.01 crore. EBITDA margin also improved slightly to 19.8%, compared to 19.2% last year, showing better operational efficiency.

New CNS Product Launch

During the quarter, the company introduced Magnesium L-Threonate (Magtein) in India through its partnership with Threotech LLC. This product strengthens Bajaj Healthcare’s CNS portfolio and highlights its collaboration with global innovators.

Management Outlook

The company expects its revenue mix to gradually shift towards exports, backed by a strong API base and approvals in regulated markets. Management also plans continued investments in R&D and capacity expansion to support long-term growth.

Also Read: Bank Nifty Slips Over 400 Points on Jan 19; RBI Lending Observations and Global Cues Drag!

About Bajaj Healthcare

Founded in 1993, Bajaj Healthcare manufactures APIs, intermediates, formulations and nutraceuticals. Its facilities cater to both advanced and emerging markets. The company has a global presence across Europe, the US, Australia, the Middle East and South America.

Conclusion

Bajaj Healthcare delivered solid Q3 numbers with strong profit and revenue growth, which boosted investor confidence and pushed the stock higher. Continued focus on exports, new product launches and R&D investments may support future growth momentum.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.